179 related articles for article (PubMed ID: 28475407)
1. Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects.
Rodgers L; Peer CJ; Figg WD
Cancer Biol Ther; 2017 Jul; 18(7):470-472. PubMed ID: 28475407
[TBL] [Abstract][Full Text] [Related]
2. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
3. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
4. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.
Lieberman R
Am J Ther; 2004; 11(6):501-6. PubMed ID: 15543092
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer. Promising advances that may alter survival rates.
Badalament RA; Drago JR
Postgrad Med; 1990 Apr; 87(5):65-7, 70-2. PubMed ID: 1690883
[TBL] [Abstract][Full Text] [Related]
6. Cancer of the prostate.
Maxwell MB
Semin Oncol Nurs; 1993 Nov; 9(4):237-51. PubMed ID: 8290819
[TBL] [Abstract][Full Text] [Related]
7. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
Schmid M; Hansen J; Chun FK
Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
[TBL] [Abstract][Full Text] [Related]
8. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
9. New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer.
Chu K; Corcoran N; Norden S; Wong LM
Anticancer Agents Med Chem; 2018; 18(7):951-957. PubMed ID: 29141559
[TBL] [Abstract][Full Text] [Related]
10. Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
Narayan VM; Konety BR; Warlick C
Int J Urol; 2017 May; 24(5):352-360. PubMed ID: 28345187
[TBL] [Abstract][Full Text] [Related]
11. Molecular markers in prostate cancer: the role in preoperative staging.
Moul JW; Merseburger AS; Srivastava S
Clin Prostate Cancer; 2002 Jun; 1(1):42-50. PubMed ID: 15046712
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy.
Ruckle HC; Klee GG; Oesterling JE
Mayo Clin Proc; 1994 Jan; 69(1):69-79. PubMed ID: 7505870
[TBL] [Abstract][Full Text] [Related]
13. Screening, risk assessment, and the approach to therapy in patients with prostate cancer.
Freedland SJ
Cancer; 2011 Mar; 117(6):1123-35. PubMed ID: 20960523
[TBL] [Abstract][Full Text] [Related]
14. Risk stratification of prostate cancer 2016.
Reiter RE
Scand J Clin Lab Invest Suppl; 2016; 245():S54-9. PubMed ID: 27533326
[TBL] [Abstract][Full Text] [Related]
15. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A
J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734
[No Abstract] [Full Text] [Related]
17. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer.
Kundra V; Silverman PM; Matin SF; Choi H
AJR Am J Roentgenol; 2007 Oct; 189(4):830-44. PubMed ID: 17885053
[TBL] [Abstract][Full Text] [Related]
18. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
Cedars BE; Washington SL; Cowan JE; Leapman M; Tenggara I; Chan JM; Cooperberg MR; Carroll PR
J Urol; 2019 Oct; 202(4):696-701. PubMed ID: 30958742
[TBL] [Abstract][Full Text] [Related]
19. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and treatment of prostate cancer].
Auvert J
Ann Urol (Paris); 1999; 33(4):259-62. PubMed ID: 10510707
[No Abstract] [Full Text] [Related]
[Next] [New Search]
